Dicerna Pharmaceuticals, Inc. (DRNA)

[ok2buy]

Vindicated on this one today. Being bought out. All cash offer at $38.50/share. Congrats to those who bought and held./ok2

[ok2buy]

US politics is driving the market lower in general. The DEMS and the REPUBS need to agree on money required to pay the existing debt and define the debt ceiling (if there is to be one). The market hates uncertainty. IMO, nothing wrong with the company. When the NAZ is moving lower by 300 - 400 points on numerous days you know there is trouble./ok2

[MomsSpaghetti]

That's one heck of a drop... and a lot got stopped up... Thoughts?

[XenaLives]

Wow - average share price >$30

Funny how they all report the same average share price.

 
 2021-08-13	13F	Rtw Investments, Lp	                                                  		     
  31.44	7,521,859	0.78	280,716	47.10				 
 2021-08-11	13F	BlackRock Inc.			            31.45	5,775,534	-5.58	215,543	37.80				 
 2021-08-13	13F	Vanguard Group Inc			     
 31.44	3,620,353	1.48	135,112	48.11				 
 2021-08-16	13F	Wellington Management Group Llp			31.45	3,299,353	-23.64	123,132	11.45				 
 2021-08-16	13F	Bain Capital Life Sciences Investors, LLC			31.44	3,080,237	0.00	114,954	45.95				 
 2021-08-16	13F	State Street Corp			     
 31.45	2,589,062	-14.99	96,624	24.08				 
 2021-08-16	13F	Price T Rowe Associates Inc /md/			31.45	1,982,925	17.11	74,003	70.93				 
  
 

https://fintel.io/so/us/drna

[XenaLives]

This?

Net Loss – Net loss was $40.8 million, or $0.53 per share, for the second quarter ended June 30, 2021, compared to a net loss of $31.8 million, or $0.43 per share, for the same period in 2020.

https://investors.dicerna.com/node/13526/html

[XenaLives]

Trying to figure out why the stock dumped after this PR:

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Aug 05, 2021


– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants

more...

https://investors.dicerna.com/news-releases/news-release-details/dicerna-reports-positive-top-line-results-phyoxtm2-pivotal

[XenaLives]

Historic short interest:

Thanks for the reminder Red...

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

Dicerna Pharmaceuticals, Inc. - Common Stock 
 Settlement Date	Short Interest	Percent Change	 
 Average Daily Share Volume	Days to Cover 
  
 09/15/2021	4,126,869	0.11	 914,655	4.51 
 08/31/2021	4,122,137	(19.29)	1,163,697	3.54 
 08/13/2021	5,107,461	9.86	1,938,271	2.64 
 07/30/2021	4,649,214	(2.20)	 630,504	7.37 
 07/15/2021	4,753,763	19.05	 742,954	6.40 
 06/30/2021	3,993,134	(19.41)	 794,900	5.02 
 06/15/2021	4,954,651	(2.49)	 703,160	7.05 
 05/28/2021	5,080,919	(8.42)	 652,085	7.79 
 05/14/2021	5,547,789	(2.95)	 669,937	8.28 
 04/30/2021	5,716,157	2.64	 604,337	9.46 
 04/15/2021	5,569,312	4.58	 510,702	10.91 
 03/31/2021	5,325,524	3.22	 839,178	6.35 
 03/15/2021	5,159,496	3.86	 908,857	5.68 
 02/26/2021	4,967,839	7.46	 657,667	7.55 
 02/12/2021	4,622,947	(4.76)	 631,608	7.32 
 01/29/2021	4,854,056	(0.06)	 814,938	5.96 
 01/15/2021	4,856,795	(6.76)	 685,284	7.09 
 12/31/2020	5,208,863	(11.94)	 620,536	8.39 
 12/15/2020	5,915,239	1.85	 692,346	8.54 
 11/30/2020	5,807,929	0.68	 382,409	15.19 
 11/13/2020	5,768,562	(0.36)	 564,424	10.22 
 10/30/2020	5,789,376	24.06	 602,784	9.60 
 10/15/2020	4,666,501	(1.74)	 428,490	10.89 
 09/30/2020	4,749,326	22.31	 525,176	9.04 
 

[XenaLives]

Institutional Shares 69,547,052 - 89.47% (ex 13D/G)

Institutional Ownership and Shareholders
Dicerna Pharmaceuticals Inc (US:DRNA) has 429 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 69,547,052 shares. Largest shareholders include Rtw Investments, Lp, BlackRock Inc., Vanguard Group Inc, Wellington Management Group Llp, Bain Capital Life Sciences Investors, LLC, State Street Corp, Price T Rowe Associates Inc /md/, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Aquilo Capital Management, LLC, and IWM - iShares Russell 2000 ETF.

Dicerna Pharmaceuticals Inc (US:DRNA) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

https://fintel.io/so/us/drna

[ok2buy]

Added again last week on this one. Buy and hold, should move back up. Best of luck to the longs./ok2

[ok2buy]

Bought today with the roll back. Institutions own 85 % of the stock. Will hold if necessary, money in the bank./ok2

[PennyStock Alert]

will be interesting after the 1/10 with 6.2 mil shares o/s instead of the current 62 mil

[wiltonio]

Domain Partners VIII, L.P. has filed a new activist 13D, reporting 14.9% ownership in $DRNA - https://fintel.io/so/us/drna

[ValueInvestor15]

Dicerna Pharma $DRNA has little Margin of Safety for Value Investors before earnings Wednesday:

Fair Value Source

[Warchest]

+.25 !!

[Warchest]

chart looking good !!!

[INTL]

Possible breakout

[ClayTrader]

* * $DRNA Video Chart 09-29-16 * *

Link to Video - click here to watch the technical chart video

[stocktrademan]

$DRNA DD Notes ~ http://www.ddnotesmaker.com/DRNA

bullish
quick trade

$DRNA recent news/filings

## source: finance.yahoo.com

Wed, 17 Dec 2014 23:58:56 GMT ~ Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced ...

read full: http://www.noodls.com/view/03BF21AF94C12E65B84F7443AA9F6916484BF35C
*********************************************************

Wed, 17 Dec 2014 23:36:00 GMT ~ Dicerna Announces the Appointment of Theodore T. Ashburn, M.D., Ph.D. to Senior Vice President, Product Strategy and Operations, and Inducement Grant of Stock Options under NASDAQ Listing Rule 5635 (c)(4)

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leader in the development of RNAi-based therapeutics, today announced the appointment of Theodore T.

read full: http://finance.yahoo.com/news/dicerna-announces-appointment-theodore-t-233600639.html
*********************************************************

Mon, 15 Dec 2014 12:12:30 GMT ~ Dicerna R&D Update Webcast Reminder

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, ...

read full: http://www.noodls.com/view/B6D67345529B90360B6D6BAD66985311ACD0E760
*********************************************************

Mon, 15 Dec 2014 12:00:00 GMT ~ Dicerna R&D Update Webcast Reminder

[Business Wire] - Dicerna Pharmaceuticals, Inc. , a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, announces webcast and conference call information for its previously announced R&D Update webcast later today, December 15, 2014, at 4:30 p.m.

read full: http://finance.yahoo.com/news/dicerna-r-d-webcast-reminder-120000794.html
*********************************************************

Tue, 25 Nov 2014 14:30:15 GMT ~ Dicerna to Present at the 2014 Deutsche Bank BioFEST

[at noodls] - WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics targeting genetically defined oncology and inherited rare diseases, ...

read full: http://www.noodls.com/view/F9E1C4DA99D749941B37AA7031DE970335309AA9
*********************************************************


$DRNA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$DRNA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/DRNA/company-info
Ticker: $DRNA
OTC Market Place: Not Available
CIK code: not found
Company name: Dicerna Pharmaceuticals, Inc.
Incorporated In:


$DRNA share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$DRNA extra dd links

Company name: Dicerna Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=DRNA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=DRNA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=DRNA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/news - http://finance.yahoo.com/q/h?s=DRNA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/DRNA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=DRNA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/DRNA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Dicerna+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Dicerna+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Dicerna+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/DRNA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=DRNA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=DRNA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=DRNA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=DRNA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=DRNA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=DRNA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=DRNA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/DRNA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=DRNA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/DRNA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=DRNA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/DRNA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/DRNA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/DRNA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/DRNA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/DRNA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=DRNA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=DRNA



$DRNA DD Notes ~ http://www.ddnotesmaker.com/DRNA